Caldwell Sutter Capital Inc. Has $230,000 Holdings in GSK plc (NYSE:GSK)

Caldwell Sutter Capital Inc. lowered its position in shares of GSK plc (NYSE:GSK) by 14.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,354 shares of the pharmaceutical company’s stock after selling 938 shares during the quarter. Caldwell Sutter Capital Inc.’s holdings in GSK were worth $230,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Horizon Bancorp Inc. IN grew its position in GSK by 8.9% during the fourth quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company’s stock valued at $147,000 after purchasing an additional 323 shares in the last quarter. Cerity Partners LLC grew its position in GSK by 305.7% in the fourth quarter. Cerity Partners LLC now owns 118,233 shares of the pharmaceutical company’s stock worth $4,383,000 after acquiring an additional 89,089 shares in the last quarter. JPL Wealth Management LLC bought a new stake in GSK in the fourth quarter worth approximately $1,129,000. Thomasville National Bank grew its position in GSK by 5.3% in the first quarter. Thomasville National Bank now owns 453,795 shares of the pharmaceutical company’s stock worth $19,454,000 after acquiring an additional 23,022 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in GSK by 1.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,777,695 shares of the pharmaceutical company’s stock worth $65,883,000 after acquiring an additional 18,585 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. The Goldman Sachs Group assumed coverage on shares of GSK in a research report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 target price for the company. Berenberg Bank raised shares of GSK to a “strong-buy” rating in a research report on Thursday, June 20th. Jefferies Financial Group boosted their target price on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Citigroup raised shares of GSK to a “strong-buy” rating in a report on Monday, June 24th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $50.00.

GSK Price Performance

Shares of GSK stock traded up $0.25 during trading on Wednesday, hitting $38.46. 1,349,478 shares of the company’s stock traded hands, compared to its average volume of 3,635,359. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58. The firm’s fifty day moving average price is $42.41 and its 200 day moving average price is $41.26. GSK plc has a twelve month low of $33.67 and a twelve month high of $45.92. The company has a market cap of $79.71 billion, a PE ratio of 13.87, a PEG ratio of 1.16 and a beta of 0.64.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.15. GSK had a net margin of 14.62% and a return on equity of 51.54%. The business had revenue of $9.34 billion for the quarter, compared to analyst estimates of $8.98 billion. Analysts forecast that GSK plc will post 4.11 earnings per share for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be given a dividend of $0.3762 per share. This is a positive change from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 annualized dividend and a dividend yield of 3.91%. The ex-dividend date is Thursday, May 16th. GSK’s payout ratio is 53.26%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.